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DNA methylationChemicals that affect cellular differentiation through epigenetic mechanisms have potential utility in treating a
wide range of diseases. Hydralazine decreasesDNAmethylation in some cell types but its effect ondifferentiation
has not been well explored. After ﬁve days of exposure to hydralazine, P19 embryocarcinoma cells displayed a
giant cell morphology and were binucleate, indicative of a trophoblast-like morphology. Other trophoblast-like
properties included the intermediary ﬁlament Troma-1/cytokeratin 8 and the transcription factor Tead4. A
decrease in CpG methylation at three sites in the TEAD4 promoter and the B1 repeated sequence was observed.
Knocking down expression of Tead4with siRNA blocked the increase in Troma-1/cytokeratin 8 and over expres-
sion of Tead4 induced the expression of Troma-1/cytokeratin 8. Cells treated for 5 dayswith hydralazinewere no
longer capable of undergoing retinoic acid-mediated neuronal differentiation. An irreversible loss of the plurip-
otent transcription factor Oct-4 was observed following hydralazine exposure. In summary, hydralazine induces
P19 cells to assume a trophoblast-like phenotype by upregulating Tead4 expression through a mechanism in-
volving DNA demethylation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Interest in the epigenetic basis of diseases such as neurodegenera-
tive diseases, schizophrenia, autoimmunity and cancer has prompted
interest in identifying drugs which target enzymes involved in regula-
tion of the epigenome. The aim is to identify drugs that could alter the
differentiation pattern of cells through effects on their methylome. In
cancer treatment, drugs that alter differentiation will likely produce
fewer secondary effects than chemicals that are cytotoxic. Interestingly,
many chemicals that have recently been shown to modify histone and
DNA methylation have been previously used both clinically and in the
laboratory for studies on cellular differentiation. The effectiveness of
sodium valproate, for example, in epilepsy treatment is thought to be
due to increasing levels of the inhibitory neurotransmitter GABA by
direct inhibition of GABA transaminase [1] and succinic semialdehyde
dehydrogenase [2] but a secondary mechanism could be through inhi-
bition of histone deacetylase [3]. Other chemicals such as the short
chain fatty acid butyric acid [4,5] and fungistatic antibiotics trichostatins
were ﬁrst shown to induce differentiation of leukemic cells to hemato-
poietic lineages [6] before the demonstration that they inhibit histone
deacetylation [7–9]. In changing DNA methylation, 5′azacytidine has
been shown to induce differentiation in several cell culture models+1 443 923 2695.
. O'Driscoll),
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l rights reserved.including the P19 cell line to cardiomyocytes [10], and Ch310T1/2
cells to striated muscle, adipocytes, and chondrocytes [11]. The chemi-
cal is now recognized as a powerful inhibitor of DNAmethyltransferase
1, though it was synthesized as an antimitotic for use in chemotherapy
[12].
Several non-nucleoside chemicals, such as hydralazine (Hyd), pro-
caine, and (−)-epigallocatechin-3-gallate [13], have also been shown
to decrease DNA methylation. Hyd was suggested to increase expres-
sion of CD70 by decreasing promotermethylation in T-derived lympho-
cytes [14] and to induce expression of adenomatous polyposis coli by
decreasing the methylation of its promoter sequence in HeLa and
CaSki cells [15]. More recent studies have shown decreases in methyla-
tion of sarcoplasmic reticulumCa2+ ATPase in cardiomyocytes [16] but,
unlike 5′azacytidine, the mechanism is unclear. In T cells, Hyd was
suggested to decrease DNA methylation by inhibiting extracellular
related kinase activity [17] whereas in CHO cells investigators found a
decrease in expression of DNA methyltransferase 1 [18]. A molecular
modeling approach indicates thatHyd and 5′azacytidine interactwithin
the DNA methyltransferase catalytic site [19]. Another substantial ben-
eﬁt is that Hyd has been used to treat hard-to-control blood pressure for
over thirty years and few side effects have been reported [20]. Whether
Hyd alters cell differentiation has been largely unexplored.
We examined the effect of Hyd on early embryonic differentiation
using the P19 embryonic carcinoma cell line. P19 cells are an appropri-
ate model for our study due to their multipotency. P19 cells are capable
of differentiating to neural [21,22] and mesenchyme lineages [23,24] in
vitro. We reasoned that P19 cells and other multipotent cell types have
461C.M. O'Driscoll et al. / Biochimica et Biophysica Acta 1833 (2013) 460–467the greatest potential to differentiate in response to drugs that target
the epigenome. In this study, we demonstrate that low concentrations
of Hyd decrease DNA methylation at several loci and induced P19 cells
to express trophoblast-like properties.
2. Materials and methods
2.1. P19 cell culture
P19 cells were obtained from ATCC (Manassas, VA) grown in
α-MEM, 7.5% bovine calf serum and 7.5% fetal bovine calf serum
(growth media) at 37 °C 5% CO2. They were maintained in culture
for up to 16 passages by passing cells by scraping. Cells were plated
at a density of approximately 4000 cells/cm2 for the different assays.
Hyd was obtained from Sigma and prepared fresh in phosphate buff-
ered saline prior to treatment.
2.2. Retinoic acid treatment and neuronal differentiation
Cells were plated at 106 cells/bacteriological 10 cm petri plate in
growth media with 500 nM retinoic acid to allow the formation of
embryoid body-like structures. After 3 days, spherical embryoid bodies
were harvested, dissociated and re-plated at 200,000 viable cells per
poly-L-lysine (0.1%) coated glass coverslips in 24-well dishes. The
cells were cultured in Neurobasal Media supplemented with B27 to
promote neuronal differentiation.
2.3. Hematoxylin/eosin staining
Cellswere allowed to attachovernight prior to treatment and exposed
to either 10 μM Hyd or 10 μM 5′Aza up to 5 d. After treatment the cells
were washed with PBS and ﬁxed in 4% paraformaldehyde. The ﬁxed
cells were permeabilized in 100% methanol and stained with eosin and
hematoxylin. Coverslips were viewed on a Zeiss Axioplan microscope.
The percentage of cells which altered morphological appearance
was obtained by counting a minimum of 100 total cells from 3 sepa-
rate experiments, cells were characterized as altered when they dem-
onstrated a larger cell body, bi or multinucleation and expression of
Troma-1/cytokeratin-8 staining.
2.4. Immunocytochemistry
Cells were washed and ﬁxed with 4% paraformaldehyde for 15 min
and permeabilized/blocked in 5% normal goat serum, 0.1% triton-x 100
in PBS. Monoclonal antibodies against Troma-1/cytokeratin-8 (Devel-
opmental Studies Hybridoma Bank, The University of Iowa, Ames, IO)
at 1:25 dilution, rabbit antibody against Oct4 (ab19857, Abcam, Cam-
bridge, MA) at 1:100 dilution, a mouse monoclonal antibody against
β-III tubulin clone SDL.3D10 (Sigma), and amonoclonal Tead4 antibody
at 1:100 (H00007004-M01, Abnova) were obtained. Coverslips were
incubated with primary antibody overnight at 4 °C, washed in PBS,
and incubated with secondary antibody (rabbit anti-mouse IgG labeled
with FITC or goat anti-rabbit IgG labeled with rhodamine) at a 1:200
dilution for 2 h at room temperature. The coverslips were washed
three times and mounted with Prolong gold with DAPI (Invitrogen,
Carlsbad, CA). The slides were viewed on the Zeiss Axioplan microscope.
2.5. Western blotting
Cells were scraped and lysates were prepared in 60 μl of RIPA
(PBS, 1% Igepal, 0.5% w/v deoxycholic acid, 0.1% SDS) buffer with
protease inhibitor cocktail set I and phosphatase inhibitor cocktail
set II (Calbiochem, La Jolla, CA). Pellets were sonicated to complete
lysis. Protein concentration was determined by Bradford assay using
bovine serum albumin (BSA) as the standard. Cell lysates were boiled
for 4 min in sample buffer containing 0.31 M Tris–HCl pH 6.8, 1%SDS, 5% glycerol, 3.6 M β-mercaptoethanol, 5 mM PMSF, and 0.05%
bromophenol blue. 25 μg of protein was separated on 4–20% gradient
gels (Cambrex, East Rutherford, NJ) at 120 V. The proteins were trans-
ferred to nitrocellulose membranes at 100 V for 90 min. Nitrocellulose
membranes were blocked with Odyssey blocking buffer (Licor) and
incubated with appropriate primary antibody overnight. Secondary an-
tibody (Licor) was diluted 1:10,000 in 1:1 Odyssey buffer: PBS and 0.1%
Tween and incubated with membrane for 1 h. The level of antibody
binding was measured on the Licor Odyssey system and normalized to
β-actin.
2.6. Transfections
A Tead4 mammalian expression plasmid was obtained from Open
Biosystems (MHS1010-58160). This plasmid expresses the full length
TEAD cDNA in a pCMV-Sport6 plasmid. The plasmid was transfected
at a concentration of 200 ng/cm2 with Lipofectamine 2000. An empty
pCMV-sport6 plasmidwas used as a negative control andwas transfected
at the same concentration. The TET expression vector expressing the cat-
alytic domain of TET was a gift from the laboratory of Dr. Hongjun Song
[25]. siRNA transfections were performed also using Lipofectamine 2000
(Invitrogen). For Tead4 knockdown, siRNA Silencer Select Pre-silencer
siRNA s74939was transfected at a concentration of 5 nM (Ambion). Con-
trol siRNA #2 was also used at the same concentration to control for
nonspeciﬁc effects (Ambien).
2.7. RT-PCR
RNA was isolated using Tirol reagent (Invitrogen) according to the
manufacturer's instructions. 5 μg of RNA was converted to cDNA using
the superscript II kit (Invitrogen). RT-PCRwas performedwith Platinum
Taw (Invitrogen), 1.5 mM MgCl2, 200 nM dots, 200 nM each primer,
and 1× PCR buffer.





R-5′-GAGACAGGCGCTTTCTCTTG-3′2.8. Methylation speciﬁc PCR
PCR for methylated and unmethylated B1 repetitive elements was
carried out as previously described [26]. Brieﬂy DNA was extracted
from treated P19 cells using the GenElute Mammalian DNA extraction
kit (Sigma) and quantiﬁed. 2 μg of DNA was bisulﬁte modiﬁed by in-
cubation overnight at 50 °C with 0.5 mM hydroquinone and 2.5 M
sodium bisulﬁde. The bisulﬁte modiﬁed DNA was isolated using the
Wizard DNA clean-up system (PR omega, Madison, WI) and stored
at−20 °C until use. PCR ampliﬁcation was performed in a 25 μl reac-
tion mixture containing Platinum Taq with 0.1 μM of each primer.
Primer sequences;
B1 unmethylated F 5′-TAACCTCAAACTCAAAAATCCACC-3′
B1 unmethylated R 5′-GTTGGGTGTAGTGGTATATATTTTTAATTTTA-3′
B1 methylated F 5′-CTCGAACTCAAAAATCCGCC-3′
B1 methylated R 5′-GTCGGGCGTAGTGGTATATATTTTT-3′.
PCR products were resolved on a 1.5% agarose gel and visualized
under UV light.
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One microgram of DNA was bisulﬁte converted using the EpiTect
Bisulﬁte kit (Qiagen). Quantitative DNA methylation analysis was
conducted by pyrosequencing a 31 base pair sequence using 15 ng
of bisulﬁte treated DNA. Methylation of three CpGs was measured
using the following sequencing primer: GGGGAGGGCTGGCGAGGGA
AAGCGGTGGCGG. PCR was carried out for 45 cycles of 45 s at 94 °C,
45 s at 55 °C, and 45 s at 72 °C, with a ﬁnal extension step at 72 °C for
1 min using the mouse Tead4 Pyromark assay (Qiagen).
2.10. DNA dot blot
P19 cells were exposed to Hyd for up to 8 h and DNA was imme-
diately isolated using the GenElute Mammalian DNA genomic DNA
miniprep kit (Sigma). The DNA was denatured with NaOH and heat
and a vacuum manifold was used to immobilize the DNA on nitrocel-
lulose paper. DNA was ﬁxed to the membrane by vacuum baking at
80 °C. The membrane was then blocked and probed with antibodies
against 5 hydroxymethylcytosine (Active Motif) and single stranded
DNA (Abcam) for normalization. Binding was visualized using the
Licor Odyssey.
2.11. In vivo treatment of mice with Hyd
Female Swiss Webster mice (Charles River) at 6 weeks of age were
treated with 200 μg/l Hyd in the drinking water for one week and
mated overnight. At day 4.5 p.c., pregnant mice were anesthetized
and given an intercardiac injection of 0.1% solution of Chicago blue to
stain implantation sites. After 30 s, uteri were removed, cleaned and
weighed and homogenized for Western blotting.
3. Results
3.1. Hyd decreases DNA methylation and cell morphology
Hyd has been reported to decrease DNA methylation in some cell
lines but not others [27]. The methylation speciﬁc-PCR assay was
used to qualitatively assess the effects of Hyd on P19 cells by compar-
ing methylated and unmethylated forms of the B1 repetitive element.
In controls and cultures treated with Hyd for 15 min, very little
unmethylated B1 sequence was detected compared to the levelFig. 1. Hyd treatment modiﬁes morphology and increases unmethylated B1 sequence in P19
(0) or treated with Hyd for 15, 60, and 240 min. PCRs were performed for both methylated (
on a 1.5% agarose gel and visualized under UV light. (A) Cultures treated 5 days with 10 μM
multinucleated cells (B).of methylated sequence. After 60 min of treatment, the levels of
unmethylated and methylated B1 sequence were similar. Even after
4 h, the level of unmethylated B1 sequence was elevated (Fig. 1A).
We alsomade a qualitative assessment of differentiation by examin-
ing morphological changes in cells treated with Hyd. P19 cells have
the potential of differentiating to neurons and muscle cells, both cell
types display distinct andwell characterizedmorphologies.Morpholog-
ical changes were observed in a subpopulation of P19 cells treated with
Hyd but the changes were not reminiscent of neurons or muscle. These
cells were larger than untreated cells andmulti nucleated (Fig. 1B). The
morphology of the cells was similar to reports describing induction in
differentiation of mouse embryonic stem cells to trophoblasts by
knocking out Oct4 expression [28,29]. We found that 11±3% of cells
underwent the morphological transition characterized by a larger cell
body, ﬂattened appearance and multinucleation. In the absence of Hyd,
cells displaying the morphological transition were not observed. Simi-
larly, the morphological changes were not observed with the DNA
methyltransferase 1 inhibitor 5′azacytidine. It is possible that the differ-
ences between 5′azacytidine and Hyd were due to the mechanisms by
which these two chemicals decrease methylation or that effects on
morphology were unrelated to decreases in DNA methylation.3.2. Hyd treatment increases Tead4 expression and decreases methylation
at the TEAD4 promoter
We further investigated the effects of Hyd in inducing trophoblast-
like properties. Tead4 is one of the earliest transcription factors to appear
during embryogenesis and was proposed to initiate the differentiation of
trophoblasts [30]. An increase in Tead4mRNA levels was observed at 1 h
and 24 h after treatment with Hyd (Fig. 2A). The levels returned to basal
levelswithin 72 hof treatment. An increase in levels of Tead4proteinwas
observed at 72 h after treatment (Fig. 2B). Because Hyd decreases meth-
ylation at the B1 repeated sequence, we investigated whether it de-
creased methylation speciﬁcally at the TEAD4 promoter. Three CpG
sites were identiﬁed in the TEAD4 promoter as possible sites of demeth-
ylation and were assessed by pyrosequencing (Fig. 3). A signiﬁcant
decrease was observed in the level of methylation at site 2 at 1 h and de-
creases were observed at the other sites at 2 h after treatment with Hyd.
Levels of methylation remained lower than control at even 8 h. Similarly,
a 24 h treatment with 5′azacytidine resulted in decreases in methylation
of all three CpGs in the TEAD4 promoter.cells. Methylation speciﬁc PCR was performed on DNA isolated from untreated P19 cells
M) and unmethylated (U) forms of the B1 repetitive element. PCR product was resolved
Hyd or 10 μM 5′azacytidine were stained with eosin and hematoxylin. * indicates larger
Fig. 2. Hyd increases expression of Tead4. Tead4 mRNA was analyzed by RT-PCR in P19 cells treated with Hyd for up to 3 d (A) and protein levels were determined byWestern blots
(B). Results for the western blot are normalized to β-actin and are expressed as percentage of the control and presented as a mean of triplicate cultures±S.E.M. Representative blots
of single cultures are shown below the graphs. *pb0.05 using ANOVA with Dunnett's multiple comparisons post hoc test. A representative blot is shown below the graph.
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cytokeratin-8 levels and transcription factors
The intermediary ﬁlament Troma-1/cytokeratin-8 is commonly
used as a marker to study trophoblasts [31]. Indeed, the expression of
Troma-1/cytokeratin-8 was detected by immunocytochemistry in P19
cells treated with Hyd (Fig. 4A). Interestingly, only cells displaying
morphological alterations including increased size and multinucleation
expressed Troma-1/cytokeratin-8. In contrast, cells that did not under-
go the morphological transformation expressed Oct4 but not Troma1/Fig. 3. Hyd decreases DNA methylation at the TEAD4 promoter. Pyrosequencing was used to
from untreated cultures, and cultures treated with Hyd for up to 8 h, 5′azacytidine (5′Aza) w
each site (B) is expressed as the percentage of methylation and presented as a mean±S.E.M
post hoc test.cytokeratin-8. Increased levels of Troma-1/cytokeratin-8 were con-
ﬁrmed on Western blots (Fig. 4B). Interestingly, lower levels of Oct4
and higher levels of Troma-1/cytokeratin-8 were observed in homoge-
nates prepared from early embryo implantation sites isolated from
dams given Hyd before coitus and 3 days post coitus (Supplementary
Fig. 1).
Other trophoblast transcription factors were expressed but their
responsiveness to Hyd varied. For example, increased expression of
Cdx2 was observed but the expression of Eomes was initially very
high and at three days after Hyd treatment. Very little expression ofanalyze the methylation status of three cytosines in the Tead4 promoter. DNA isolated
as used as a positive control. The three sites of interest are illustrated in A. The data for
. *pb0.05 and **pb0.01, ***pb0.001 using ANOVA with Dunnett's multiple comparisons
Fig. 4. Hyd increases expression of Troma-1/cytokeratin-8 in P19 cells. P19 cells cultured for 5 d in the presence or absence of 10 μM Hyd and stained with a 1:25 dilution of an-
tibody against Troma-1/cytokeratin 8 (green) and a 1:100 Oct-4 (red) diluted antibody and then incubated with DAPI to stain nuclei blue (A). Western blots were conducted on
cultures treated with 10 μM Hyd for 5 d. The intensities of the bands in the blots were measured and normalized to actin. The data are expressed as a percentage of the control
(absence of Hyd) and presented as a mean of 3 separate experiments±S.E.M. Representative blots are shown below the graphs. *pb0.05 using ANOVA with Dunnett's multiple
comparisons post hoc test.
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contrast, increases in levels of Hand1, Eomes, and Cdx2 occur during
differentiation of mouse embryonic stem cell lines to trophoblasts in-
duced by knocking down Oct4 [32] or by inducing with gelatin [33].
These differences could reﬂect differences in the types of cells in the
trophectoderm lineage being formed [34] or differences due to the
stimulus and/or the cell line.Fig. 5. Involvement of Tead4 in expression of Troma-1/cytokeratin 8. Troma-1/cytokeratin
treated with Hyd for 24 h after transfection with either siRNA scramble (siRNA C) or siR
shown (C). Troma-1/cytokeratin 8 and GAPDHmRNA were also measured by real time-PCR
vector (B). Below the graph is a western blot of P19 cells transfected with the empty pCMV
multiple comparisons post hoc test.3.4. Tead4 modiﬁes expression of Troma-1/cytokeratin-8
The inﬂuence of Tead4 on Troma-1/cytokeratin-8 expression was
examined by knocking down Tead4 and expressing high levels of
Tead4. We were able to reduce the level of Tead4 mRNA at 24 h after
transfecting cells with a Tead4 siRNA (Fig. 5C). Interesting, Hyd failed
to induce expression of Troma-1/cytokeratin-8 in P19 cells expressing8 and GAPDH mRNA were measured by real time-PCR in RNA isolated from P19 cells
NA Tead4 (A). A representative RT-PCR of the knockdown with Tead4 siRNA is also
in RNA isolated from P19 cells transfected expressing the CMV-driven Tead4 expression
-sport6 plasmid or pCMV-sport6 TEAD4 (D). ***pb0.001 using ANOVA with Dunnett's
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cells transfected with control siRNA. Cell transfectedwith the Tead4 ex-
pression vector displayed an increase in Troma-1/cytokeratin-8 expres-
sion (Fig. 5B).3.5. Hyd treated cells lose their multipotent potential and no longer dif-
ferentiate to neural cells
The decreases in expression of Oct4 suggested that Hyd treatment
blocks P19 cells' multipotency. To examine the effect of Hyd on neuronal
differentiation, P19 cells were pre-treated with 10 μM Hyd for 3 d and
then treated with retinoic acid for 3 d (without Hyd). Cells pre-treated
with Hyd failed to form the spherical embryoid body structures that
normally form after treatment with retinoic acid (not shown). When
the Hyd pre-treated cells were re-plated on poly-lysine coated plates,
neurites were not observed (Fig. 6A). Cells Hyd pre-treatment responded
to retinoic acid and displayed outgrowths characterized by beta-III tubu-
lin staining.
The failure to respond to retinoic acid even when Hyd was with-
drawn suggests that the effects of Hyd on multipotency were irrevers-
ible. Oct4 levels began to decline at 72 h after Hyd was added to P19
cell monolayers and remained below basal levels at 120 h after treat-
ment (Fig. 6B). In order to investigate the reversibility of the loss of
Oct4, cells were treated with Hyd for 4 days, passaged and then allowed
to grow for a further 4 days without Hyd. We also found that levels of
Oct4 in Hyd treated cells did not increase even after Hydwas withdrawn.Fig. 6. Hyd decreases the multipotency of P19 cells. P19 cells were exposed to retinoic acid
equivalent volume of PBS. Cells were allowed to differentiate for either 3 or 5 d and stained w
mounted in Prolong with DAPI (A). Levels of Oct4 were measured by Western blots in P19
P19 cells treated for 4 days with Hyd (+), or 4 days with Hyd followed by 5 days without H
sured and normalized to actin. The data are expressed as percentage of control and presented
graphs. *pb0.05 and **pb0.01, using ANOVA with Dunnett's multiple comparisons post hoCells treated with Hyd for 4 d and replated in fresh media without Hyd
for 5 d displayed levels of Oct4 that were similar to cells treated with
Hyd for 5 d (Fig. 6C).4. Discussion
Here we demonstrate that Hyd induces the P19 embryonic carcino-
ma cell line to display a trophoblast-like phenotype. In embryogenesis,
the development of trophoblasts is the ﬁrst identiﬁable differentiation
event occurring at the blastocyst andwill give rise to the few differenti-
ated cell types in the fetal side of the placenta. The trophoblast-like
properties expressed by P19 cells include increases in the trophoblast
transcription factor Tead4 and the expression of the intermediary
ﬁlament Troma-1/cytokeratin-8. The large size and multinucleation
displayed by cells positive for Troma-1/cytokeratin-8 are also features
resembling trophoblasts [35,36]. Cells expressing Troma-1/cytokeratin-8
no longer expressed Oct4 and total levels of Oct4 were much lower.
Indeed, the expression of the trophoblast-like phenotype was associated
with the loss in potential to differentiate to neurons and possibly other
cell types. Similarly, a previous study reported the induction of tropho-
blast giant cells by P19 cells ectopically expressing an Oct4 dominant
negative though the expression of biochemical features speciﬁc to
trophoblast-like cells was not studied [37].
The expression of Troma-1/cytokeratin-8 was modiﬁed by Tead4.
Knocking down Tead4 by siRNA reduced expression and over ex-
pressing Tead4 increased expression. Tead4 belongs to the family ofto initiate neuronal differentiation following a 5 day treatment with 10 μM Hyd or an
ith mouse monoclonal antibody against β-IIII tubulin and a FITC labeled secondary and
cells treated for up to 120 h with 10 μM Hyd (B). Levels of Oct4 were also measured in
yd (+/−), or without Hyd (−) (C). The intensities of the bands in the blots were mea-
as a mean of triplicate experiments±S.E.M. Representative blots are shown below the
c test.
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a four member family, that bind to the same DNA consensus sequence
[38]. To our knowledge Tead4 is the earliest transcription factor acti-
vated after fertilization [35]. Other investigators also observed a rela-
tion between Tead4 and the induction to a trophoblast lineage. Mouse
embryonic stem cells from Tead4 −/− mice failed to differentiate to
trophoblast stem cells or express the early Cdx2 transcription factor
[30]. Indeed, Tead4 is required for the expression of two parallel
trophoblast signaling pathways transcription, one is regulated by
Cdx2 [35,30] and the other is regulated by Gata3 [39]. A model has
been developed suggesting that Tead4 triggers a critical event early
in the establishment of trophoectoderm, sometime during the 8-cell
to morula transition, but does not regulate expression of all genes
involved in formation of trophectoderm [30].
One possible mechanism for the increases in Tead4 expression is
through demethylation. Three CpG sites within the TEAD4 promoter
displayed less methylation in cells treated with Hyd for 2 h. A decrease
in methylation could be due to a passive or active mechanism. Passive
mechanisms would be caused by a decrease in the activity of DNA
methyltransferases, which methylate during DNA synthesis and DNA
repair (Leonhardt, Page et al., 1992) (Mortusewicz, Schermelleh et al.,
2005). A passive mechanism, however, would be less likely because
very few cells are going through S phase in 1–2 h of Hyd treatment.
An active mechanism might involve hydroxymethylation by the TET
followed by deamination and base excision repair pathway. An increase
in levels of 5-hydroxymethylcytosine (Supplementary data Fig. 3) was
not observed though it might be possible that Hyd had direct interac-
tions with methylcytosine [40] or provoking a signaling pathway and
downstream events not yet identiﬁed. Hyd was suggested to decrease
DNA methylation by inhibiting the ERK pathway in T cells [14]. Hyd is
also known to activate hypoxia inducible factor [41] and disrupt calci-
um signaling [16].
In summary, Hyd induces DNA demethylation and expression of
trophoblast-like properties in P19 cells. Similarly, Hyd was shown to
induce demethylation in a number of other cell types though it is
not active in all cell types [27]. By understanding the mechanism by
which Hyd induces DNA demethylation, we could better predict the
types of tumors that would be responsive to Hyd and its potential
role in epigenetic modulation of disease states.
Supplementary data to this article can be found online at http://
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